Mirum Pharmaceuticals (NASDAQ: MIRM)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.340 | -1.170 | 0.1700 | ||||
REV | 8.460M | 12.892M | 4.432M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Mirum Pharmaceuticals (NASDAQ: MIRM) through any online brokerage.
Other companies in Mirum Pharmaceuticals’s space includes: Chinook Therapeutics (NASDAQ:KDNY), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL), FibroGen (NASDAQ:FGEN) and TG Therapeutics (NASDAQ:TGTX).
The latest price target for Mirum Pharmaceuticals (NASDAQ: MIRM) was reported by Raymond James on Friday, May 6, 2022. The analyst firm set a price target for 75.00 expecting MIRM to rise to within 12 months (a possible 193.20% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Mirum Pharmaceuticals (NASDAQ: MIRM) is $25.58 last updated May 20, 2022, 8:00 PM UTC.
There are no upcoming dividends for Mirum Pharmaceuticals.
Mirum Pharmaceuticals’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Mirum Pharmaceuticals.
Mirum Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.